St. John Fisher University

Fisher Digital Publications
Pharmacy Faculty/Staff Publications

Wegmans School of Pharmacy

2012

Observed incidence of linezolid-associated serotonin syndrmoe
during concomitant serotonergic therapy
Melanie Woytowish
St. John Fisher University, mwoytowish@sjf.edu

Lena Maynor
West Virginia University

Follow this and additional works at: https://fisherpub.sjf.edu/pharmacy_facpub
Part of the Pharmacy and Pharmaceutical Sciences Commons

How has open access to Fisher Digital Publications
benefited you?
Publication Information
Woytowish, Melanie and Maynor, Lena, "Observed incidence of linezolid-associated serotonin syndrmoe
during concomitant serotonergic therapy" (2012). Pharmacy Faculty/Staff Publications. Paper 19.
https://fisherpub.sjf.edu/pharmacy_facpub/19
Please note that the Publication Information provides general citation information and may not be
appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit
http://libguides.sjfc.edu/citations.

This document is posted at https://fisherpub.sjf.edu/pharmacy_facpub/19 and is brought to you for free and open
access by Fisher Digital Publications at . For more information, please contact fisherpub@sjf.edu.

Observed incidence of linezolid-associated serotonin syndrmoe during
concomitant serotonergic therapy
Disciplines
Pharmacy and Pharmaceutical Sciences

Comments
Poster presented at Faculty Scholarship Celebration, St. John Fisher College, October 25, 2012.

This poster presentation is available at Fisher Digital Publications: https://fisherpub.sjf.edu/pharmacy_facpub/19

Observed incidence of linezolid-associated serotonin syndrome
during concomitant serotonergic therapy
Melanie Woytowish, PharmD1, Lena Maynor, PharmD, BCPS2
1Wegmans

School of Pharmacy St. John Fisher College, Rochester, New York
2West Virginia University School of Pharmacy, Morgantown, West Virginia

INTRODUCTION
 While confirmed cases of serotonin syndrome (SS) have been associated
with linezolid, the incidence in patients receiving linezolid in combination with
other serotonergic medications has not been well established
 Incidence in published retrospective studies ranges from 0.54% to
4.17%1-4
 The Hunter Serotonin Toxicity Criteria (HSTC) are the most widely accepted
criteria used to diagnosis SS
Any of the following in the presence of a serotonergic agent
Spontaneous clonus
Inducible clonus AND agitation OR diaphoresis
Ocular clonus AND agitation OR diaphoresis
Tremor AND hyperreflexia
Hypertonicity AND temperature > 38 C AND ocular clonus

OBJECTIVE

RESULTS
 130 unique courses of linezolid were received by 121 unique patients
 37 (28.5%) were in patients who received concomitant serotonergic therapy

Table 1. Demographic Information
n = 37
Median Age (IQR) [years]

64 (50-75)

Female (%)

25 (67.6%)

Median Length of Stay (IQR) [days]

13 (7-19)

Median Duration of Linezolid Therapy (IQR) [hours]

78 (44-167)

Pulmonary Disease

45.9%

Cardiovascular Disease

27.0%

Seizure Disorder

18.9%

Liver Disease

2.7%
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 The incidence of linezolid-associated SS in 37 patients receiving linezolid in
combination with other known serotonergic agents at a large academic
medical center was zero
 To our knowledge this is the first prospective study investigating the
incidence of linezolid-associated SS
 Limitations
 Single center
 Short study period
 Patients were not physically assessed daily by investigators
 Linezolid-associated SS is rare despite use with serotonergic therapy
at West Virginia University Hospitals
 Further observation is needed in order to describe the true incidence
of this life-threatening reaction and related risk factors
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SSRIs, selective serotonin reuptake inhibitors;
SNRIs,
serotonin
norepinephrine
reuptake
inhibitors; SGAs, second generation antipsychotics

 No patients receiving linezolid in combination with other serotonergic therapy
developed the primary outcome
 The following symptoms were observed
 Six patients were agitated
 Five during combination therapy
 Two of the five were agitated throughout admission
 The other was agitated 9 days after completion of linezolid
 One patient was diaphoretic during combination therapy
 Although the primary team did not make a diagnosis of SS, the ID consult
team listed SS on the differential for a patient hospitalized with traumatic
brain injury and sympathetic storming who had persistent fever, tachycardia,
and flushing

DISCUSSION

VRE

Prospectively determine the incidence of SS in hospitalized patients
receiving linezolid and concomitant serotonergic therapy

 IRB-approved prospective analysis
 Inclusion criteria: ≥ 18 years of age, receipt of linezolid between March 1,
2012 and June 15, 2012
 Exclusion criteria: none
 Primary outcome: development of SS, by definitive diagnosis via the primary
patient care team or by satisfying the HSTC
 Concomitant serotonergic therapy was defined as any agent known to affect
serotonin activity
 A CPOE-based report of active linezolid orders was generated daily to
capture patients for inclusion
 Electronic health records (EHR) of included patients were assessed for
signs and symptoms of SS daily until development of SS or hospital
discharge
 If documentation in the EHR suggested possible SS, the primary
patient care team was contacted to confirm
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